Clinical Trial Update: Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

View source ↗

Summary

An observational study evaluating the long-term safety of Radium-223 dichloride (Xofigo) for metastatic castration-resistant prostate cancer. Results posted on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Metastatic Castration-resistant Prostate Cancer | Status: COMPLETED | Results posted: 2025-09-05